Iovance Biotherapeutics, Inc. IOVA Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s net income?
- Iovance Biotherapeutics, Inc. (IOVA) reported net income of -$79.05M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s net income changed year-over-year?
- Iovance Biotherapeutics, Inc.'s net income increased by 32.0% year-over-year, from -$116.16M to -$79.05M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s net income has grown at a 3.4% compound annual growth rate (CAGR), from -$342.25M to -$390.98M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.